Frequently Asked Questions
In this section you can find answers to frequently asked questions about Fagron
Fagron’s strategy and operating environment
Long-term trends and shifting market dynamics are accelerating the demand for personalized medicine, transforming the landscape in which Fagron leads and innovates.
As a global leader in pharmaceutical compounding, Fagron is well-positioned to adapt to these changes, operating across multiple countries and regions. Our broad international presence allows us to align our business model and strategy with key trends that support the demand for personalized medicine.
Ageing population
Demographic shifts, such as population growth and rising life expectancy, are key drivers of demand for personalizing medicine. The increasing prevalence of chronic conditions, along with growing needs for pain management, infusion therapies, and home care, further expands the role of compounding medications. These trends underscore the importance of adapting treatments to individual patient needs, enabling proactive health management while reducing the burden on healthcare systems.
Personalization
Standard commercial medications do not always meet every patient’s needs. Compounding bridges this gap by creating tailored treatments that account for individual factors such as allergies, intolerances, precise dosage requirements, and required dosage forms, while also helping reduce side effects. Fagron Genomics is an enabler, enhancing the effectiveness of personalized treatments. These advancements allow healthcare providers to prescribe truly individualized therapies, improving patient outcomes and quality of life.
Another trend is the shift toward delivering healthcare outside traditional hospital settings. By making care more accessible, patient quality of life improves while overall costs decrease. However, this trend introduces new demands on how medications are prepared and delivered. Large pharmaceutical companies are not equipped to produce small, customized batches on demand, making tailored compounding solutions more essential than ever.
Prevention & lifestyle
Growing health awareness is a global secular mega-trend. People aspire not only to live longer but also to enjoy a higher quality of life, and prevention plays a crucial role. An expanding middle class with greater disposable income is driving increased focus on preventive health, healthy lifestyles, and early diagnosis, all of which fuel demand for personalized solutions.
Advances in technology and data analytics now make it possible to create detailed genetic profiles, enhancing our ability to predict disease risk, drug tolerance, and treatment response. These innovations are transforming healthcare by enabling more precise, individualized treatments.
Increased regulation
Increasing regulatory requirements and stricter quality standards are driving pharmacies and hospitals to outsource compounding to specialized providers. These regulations determine where and how compounding medications can be distributed, directly influencing product development and manufacturing processes. Fagron’s unwavering commitment to global regulatory compliance ensures the safety and quality of our products, reinforcing trust among healthcare providers and patients.
Accessibility
Pharmaceutical compounding plays a critical role in addressing drug shortages, ensuring essential medicines remain available even when large pharmaceutical companies discontinue production due to low demand. Drug shortages accelerate the trend toward outsourcing, and by customizing medications to meet specific patient needs, Fagron helps guarantee access to the right treatments at the right time.
Fagron’s purpose is to create the future of personalizing medicine.
Objective 1: Strengthening our global leadership in Essentials
Fagron ambitions to strengthen its #1 position in the repackaging and distribution of pharmaceutical raw materials across core markets while driving operational excellence through SKU harmonization, sourcing optimization, and regulatory preparedness.
Objective 2: Accelerating our growth in Brands
The Global Brands Strategy will be a key growth and margin driver, increasing its share of Brands & Essentials revenue. The company is scaling proven Brands globally, supported by scientific validation, prescriber engagement, and infrastructure readiness. As such, we aim to achieve a 35% contribution from Brands within the total Brands & Essentials revenue by 2030.
Objective 3: Expanding our sterile compounding services
Fagron is investing in high-quality sterile capacity and capabilities across all regions, aiming to become a leading global platform for personalized sterile medicines. Facility upgrades, automation, and regulatory strength will underpin this expansion. In this sense, the new Tampa facility is being operational in 2025 and has obtained its California license, allowing us to transition from the old site. In addition, we have announced expansions at our 503B facilities in Wichita, Kansas, and Las Vegas, Nevada, as well as at our outsourcing facility in the Netherlands. Collectively, these investments are expected to add approximately 500 million revenue in combined capacity by 2028.
Objective 4: Optimizing non-sterile compounding business
In non-sterile compounding, our focus is on margin improvement through operational leverage, automation, and improved quality processes.
In addition to innovation-driven organic growth, Fagron strives to grow through targeted acquisitions. Fagron’s business model is scalable, as a result of which immediate commercial and operational benefits of scale can be realized when integrating an acquisition. Moreover, cross-selling offers the possibility to introduce innovative products and concepts in new markets. The strategic rationale for an acquisition can be found in geographical expansion, portfolio expansion, therapeutic area expansion and/or market consolidation.
Information on this page was most recently updated on 17 February 2026.